SecBot SecBot
PRESS-RELEASE ·Filed Mar 2, 2026

OCGN

Ocugen
BULLISH
Impact 8/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Investors should monitor upcoming BLA submission in Q3 2026 and Phase 3 topline data in Q1 2027 as key catalysts. The gene-agnostic mechanism could position OCU400 as a first-in-class therapy with broad market potential.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.94
T+0 close · Mar 2, 2026 · via day close
Latest settled
−30.93%
T+60 · $1.34
Vs SPY
−40.25%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $1.94entry
  2. T+1 · 9mo ago −4.12%α −3.21% · $1.86
  3. T+5 · 8mo ago −14.43%α −13.23% · $1.66
  4. T+20 · 8mo ago −9.79%α −1.86% · $1.75
  5. T+60 · 6mo ago −30.93%α −40.25% · $1.34
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ocugen announced completion of patient enrollment in the Phase 3 liMeliGhT trial for its gene therapy OCU400 in retinitis pigmentosa (RP), with topline data expected in Q1 2027. The company also reported positive 3-year Phase 1/2 data showing durable vision improvement and a favorable safety profile, reinforcing the potential for a gene-agnostic treatment. BLA filing is on track for Q3 2026.

Key Facts

  • Enrollment completed in OCU400 Phase 3 liMeliGhT trial with 140 patients randomized 2:1 across RHO and gene-agnostic RP mutations.
  • Topline Phase 3 data expected in Q1 2027, supporting potential approval in 2027.
  • Positive 3-year Phase 1/2 data show 88% of treated eyes maintained or improved vision, with ~2-line LLVA gain sustained across mutations.
  • No new treatment-related serious adverse events reported; safety profile remains favorable.
  • Rolling BLA submission planned for Q3 2026; EMA accepts U.S. trial data for future MAA submission.

Financial Impact

Potential blockbuster revenue if approved, given no current gene-agnostic therapy for RP and ~98% of RP patients lack treatment options.

revenuevaluationmarketCap

Risk Factors

  • Phase 3 results may not replicate Phase 1/2 durability or efficacy.
  • Regulatory delays or rejection despite EMA acceptability opinion.
  • High development risk typical of gene therapies in late-stage trials.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3247241

Track record

23 reports on OCGN

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +20.49% at T+20 after the Jun 11, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  2. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  3. Nov 6, 202610d ago DEFA14A Neutral 2/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  4. Nov 6, 202610d ago DEFA14A Neutral 3/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $0.8745 to $0.8165 Now $0.7730 −11.61% ▼ −6.63% −2.22% vs SPY
  7. Oct 15, 20264w ago 8-K Neutral 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  8. Oct 14, 20264w ago 8-K Mixed 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  9. Oct 9, 20265w ago 144 Neutral 2/10 Entry $0.9472 to $0.8854 Now $0.7730 −18.39% ▼ −6.52% −6.51% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 7/10 Entry $1.33 to $1.32 Now $0.7730 −41.88% ▼ −0.75% −1.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 2, 2026